share_log

诺诚健华医药有限公司自愿披露关于ICP-332在美国完成首例受试者给药的公告

Innocare Pharmaceutical voluntarily discloses the announcement of the first dosing of ICP-332 trial subjects in the United States.

SZSI ·  Jul 24
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more